ArticleDermatology and therapy2025

Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study.

Richard B Warren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.